Orthofix Medical Inc. (OFIX) fair value analysis
Nasdaq · Updated 2026-10-19
OFIX price how computed
Valuation status
No verdict this weekOFIX: Next year's consensus is far above both what this company earned over the last four quarters and what its most recent quarter is earning.
Our model does not publish a verdict on a forecast that far from results; it is re-evaluated weekly.
- Last price
- $9.38
- Sector
- Healthcare
- 12-month range
- $8.64–$16.20
- Market cap
- $379M
- From 52-week high
- -42.1%
- Shares outstanding
- 40.4M
- Rank in Healthcare by quality score
- #168 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Orthofix Medical Inc. is a medical device company that develops and manufactures orthopedic and spine products, including biologics, orthobiologics, and fixation devices for surgical and non-surgical applications. The company operates globally, serving patients and healthcare providers across multiple international markets.
OFIX currently ranks #168 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $379M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $833M
- Net margin
- -7.4%
- EPS (TTM)
- $-0.06
- Gross margin
- 71.0%
- Debt / equity
- 0.55
- Revenue growth (3-yr avg)
- 4.9%
- Shares outstanding
- 40.4M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 60 · neutral
- 50-day average
- $9.48
- 200-day average
- $11.37
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-03
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+15.2%)
2026-03 ▲ beat (+62.1%)
2025-12 ▲ beat (+208.1%)
2025-09 ▲ beat (+66.7%)
2025-06 ▲ beat (+225.0%)
2025-03 ▲ beat (+88.9%)
2024-12 ▲ beat (+130.8%)
2024-09 ▲ beat (+146.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 3 buy · 2 hold · 0 sell (5 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $13
- Target vs last price
- +38.6%
What our data shows for OFIX
- Our model validated 13 trailing price-to-earnings windows for OFIX, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $8.64–$16.20.
- The 14-day relative strength index sits at a neutral 60.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- OFIX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent OFIX news
TickrTrends' derived news-sentiment signal for OFIX is currently leaning positive, computed from recent coverage.
- Insider Sell: President, Global Limb Recon Patrick Fisher Sells 150 Shares of Orthofix Medical Inc (OFIX) (gurufocus.com, 2026-10-05)
TickrTrends take: Patrick Fisher, President of Global Limb Recon at Orthofix Medical Inc, sold 150 shares in a recent transaction. Given TickrTrends' current undervalued assessment of OFIX, observers monitoring the Healthcare sector stock should note whether insider selling represents a shift in company confidence or remains consistent with normal portfolio management practices. The stock's undervalued positioning makes tracking insider transaction patterns particularly relevant for understanding potential catalysts that could move the valuation gap. - Juniper Investment Company, LLC Adds Orthofix Medical Inc (OFIX) -- Shares Look 30% Undervalued on GF Value (gurufocus.com, 2026-09-29)
TickrTrends take: TickrTrends currently classifies OFIX as undervalued within the Healthcare sector, which aligns with external valuation assessments suggesting the stock trades below its intrinsic value. A valuation-focused investor monitoring OFIX should track whether institutional investment activity, such as the addition to Juniper Investment Company's portfolio, correlates with closing the gap between current market price and estimated fair value. Continued institutional interest combined with the company's operational performance will be key indicators to watch for potential valuation convergence. - Orthofix Medical Inc (OFIX) Insider Sell: President, Global Limb Recon Patrick Fisher Disposes of 150 Shares (gurufocus.com, 2026-09-04)
TickrTrends take: An insider sale of this magnitude represents a relatively modest transaction, though valuation-focused investors typically monitor insider dispositions as signals of management confidence. Given TickrTrends' current undervalued assessment of OFIX within the Healthcare sector, this particular sell activity warrants observation to determine whether it reflects broader concerns about the company's prospects or represents routine portfolio management by an executive. Readers tracking the stock should continue monitoring insider transaction patterns and any accompanying regulatory filings for additional context about management's view of the company's current valuation levels.
What people are saying
Follow the OFIX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — OFIX's RSI moved from oversold into neutral territory this week, suggesting a reduction in immediate downward momentum. The stock remains classified as undervalued based on current valuation metrics within the healthcare sector.
- 2026-09-21 — TickrTrends' derived indicators for OFIX showed a shift this week as the RSI zone moved from neutral to oversold territory. The stock maintains an undervalued current valuation verdict according to TickrTrends' assessment. This oversold reading may suggest the stock has experienced recent downward price pressure within the healthcare sector.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is OFIX stock undervalued?
OFIX does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is OFIX's TickrTrends verdict?
OFIX is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does OFIX compare to other Healthcare stocks?
OFIX ranks #168 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is OFIX overbought or oversold?
OFIX's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does OFIX report earnings next?
OFIX's next earnings report is scheduled for 2026-11-03, per the published earnings calendar.
Does OFIX usually beat earnings estimates?
Over its last 8 reported quarters OFIX beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about OFIX?
Of 5 analysts covering OFIX, 3 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $13 (+38.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.